Drug class
Nicotinic acid derivative; lipid-modifying agent
Mechanism of action
Inhibits release of free fatty acids from adipose tissue and reduces circulating VLDL and LDL; triglyceride and cholesterol concentrations fall, while HDL may increase.
General use cases
- Hypertriglyceridaemia (Fredrickson type IV hyperlipoproteinaemia)
- Combined hypercholesterolaemia and hypertriglyceridaemia (Fredrickson type IIb hyperlipoproteinaemia)
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
